التفاصيل البيبلوغرافية
| العنوان: |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
| المؤلفون: |
Débora Leite Campos, Fernanda Manaia Demarqui, Mariana Cristina Solcia, Paula Carolina de Souza, Pedro Ivo da Silva Maia, Victor Marcelo Deflon, Fernando Rogério Pavan |
| المصدر: |
Biomedicines; Volume 10; Issue 10; Pages: 2398 |
| بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
| سنة النشر: |
2022 |
| المجموعة: |
MDPI Open Access Publishing |
| مصطلحات موضوعية: |
latent tuberculosis, Mycobacterium tuberculosis, treatment |
| الوصف: |
As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| Relation: |
https://dx.doi.org/10.3390/biomedicines10102398 |
| DOI: |
10.3390/biomedicines10102398 |
| الاتاحة: |
https://doi.org/10.3390/biomedicines10102398 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: |
edsbas.AB698D7C |
| قاعدة البيانات: |
BASE |